Using a novel lysin to help control Clostridium difficile infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7447-7457

  Wang, Qiong ^a   Euler, Chad W ^a,b,c   Delaune, Aurelia ^a   Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COLISTIN; GENTAMICIN; KANAMYCIN; LYSIN; METRONIDAZOLE; UNCLASSIFIED DRUG; VANCOMYCIN; AMIDASE; ANTIINFECTIVE AGENT; ENDOLYSIN; PROTEINASE; RECOMBINANT PROTEIN; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CLOSTRIDIA; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; ENZYME ACTIVE SITE; EX VIVO STUDY; HOSPITAL PATIENT; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; COLON; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GENETICS; MICROBIOLOGY; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; PEPTOCLOSTRIDIUM DIFFICILE; PH; PROPHAGE;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; CATALYTIC DOMAIN; CLOSTRIDIUM DIFFICILE; COLON; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDOPEPTIDASES; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HYDROGEN-ION CONCENTRATION; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PROPHAGES; RECOMBINANT PROTEINS; VANCOMYCIN; VIRAL PROTEINS;

EID: 84954569031     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01357-15     Document Type: Article

References (59)

1. Heinlen L, Ballard JD. 2010. Clostridium difficile infection. Am J Med Sci 340:247-252. http://dx.doi.org/10.1097/MAJ.0b013e3181e939d8.
2. Penziner S, Dubrovskaya Y, Press R, Safdar A. 2015. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother 59:1776-1781. http://dx.doi.org/10.1128/AAC.04268-14.
3. CDC. 2015, posting date. http://www.cdc.gov/HAI/organisms/cdiff/Cdiff-infect.html.
4. Bartlett JG. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145:758-764. http://dx.doi.org/10.7326/0003-4819-145-10-200611210-00008.
5. Elliott B, Chang BJ, Golledge CL, Riley TV. 2007. Clostridium difficileassociated diarrhoea. Intern Med J 37:561-568. http://dx.doi.org/10.1111/j.1445-5994.2007.01403.x.
6. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449. http://dx.doi.org/10.1056/NEJMoa051639.
7. MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe AC, Laing F, Henwick S. 2006. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from eastern and western Canada. J Clin Microbiol 44:2147-2152. http://dx.doi.org/10.1128/JCM.02563-05.
8. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-1084. http://dx.doi.org/10.1016/S0140-6736(05)67420-X.
9. Leffler DA, Lamont JT. 2009. Treatment of Clostridium difficileassociated disease. Gastroenterology 136:1899-1912. http://dx.doi.org/10.1053/j.gastro.2008.12.070.
10. Monaghan T, Boswell T, Mahida YR. 2008. Recent advances in Clostridium difficile-associated disease. Gut 57:850-860. http://dx.doi.org/10.1136/gut.2007.128157.
11. Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C. 2005. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40:1591-1597. http://dx.doi.org/10.1086/430315.
12. Surawicz CM, Alexander J. 2011. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 8:330-339. http://dx.doi.org/10.1038/nrgastro.2011.59.
13. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
14. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. 2000. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38:2386-2388.
15. Alzahrani N, Johani SA. 2013. Emergence of a highly resistant Clostridium difficile strain (NAP/BI/027) in a tertiary care center in Saudi Arabia. Ann Saudi Med 33:198-199. http://dx.doi.org/10.5144/0256.4947.2013.198.
16. Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. 2013. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother 57:2690-2693. http://dx.doi.org/10.1128/AAC.00548-13.
17. Rohlke F, Stollman N. 2012. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol 5:403-420. http://dx.doi.org/10.1177/1756283X12453637.
18. Agito MD, Atreja A, Rizk MK. 2013. Fecal microbiota transplantation for recurrent C difficile infection: ready for prime time? Cleveland Clin J Med 80:101-108. http://dx.doi.org/10.3949/ccjm.80a.12110.
19. Hell M, Bernhofer C, Stalzer P, Kern JM, Claassen E. 2013. Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Beneficial Microbes 4:39-51. http://dx.doi.org/10.3920/BM2012.0049.
20. O'Horo JC, Jindai K, Kunzer B, Safdar N. 2014. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 42:43-59. http://dx.doi.org/10.1007/s15010-013-0496-x.
21. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ. 2008. Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104:1-13. http://dx.doi.org/10.1111/j.1365-2672.2007.03498.x.
22. Petty NK, Evans TJ, Fineran PC, Salmond GP. 2007. Biotechnological exploitation of bacteriophage research. Trends Biotechnol 25:7-15. http://dx.doi.org/10.1016/j.tibtech.2006.11.003.
23. Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, Narbad A. 2010. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16:549-554. http://dx.doi.org/10.1016/j.anaerobe.2010.08.006.
24. Goh S, Riley TV, Chang BJ. 2005. Isolation and characterization of temperate bacteriophages of Clostridium difficile. Appl Environ Microbiol 71:1079-1083. http://dx.doi.org/10.1128/AEM.71.2.1079-1083.2005.
25. Goh S, Ong PF, Song KP, Riley TV, Chang BJ. 2007. The complete genome sequence of Clostridium difficile phage phiC2 and comparisons to phiCD119 and inducible prophages of CD630. Microbiology 153:676-685. http://dx.doi.org/10.1099/mic.0.2006/002436-0.
26. Govind R, Fralick JA, Rolfe RD. 2006. Genomic organization and molecular characterization of Clostridium difficile bacteriophage PhiCD119. J Bacteriol 188:2568-2577. http://dx.doi.org/10.1128/JB.188.7.2568-2577.2006.
27. Mayer MJ, Narbad A, Gasson MJ. 2008. Molecular characterization of a Clostridium difficile bacteriophage and its cloned biologically active endolysin. J Bacteriol 190:6734-6740. http://dx.doi.org/10.1128/JB.00686-08.
28. Horgan M, O'Sullivan O, Coffey A, Fitzgerald GF, van Sinderen D, McAuliffe O, Ross RP. 2010. Genome analysis of the Clostridium difficile phage PhiCD6356, a temperate phage of the Siphoviridae family. Gene 462:34-43. http://dx.doi.org/10.1016/j.gene.2010.04.010.
29. Mahony DE, Bell PD, Easterbrook KB. 1985. Two bacteriophages of Clostridium difficile. J Clin Microbiol 21:251-254.
30. Nagy E, Foldes J. 1991. Electron microscopic investigation of lysogeny of Clostridium difficile strains isolated from antibiotic-associated diarrhea cases and from healthy carriers. APMIS 99:321-326. http://dx.doi.org/10.1111/j.1699-0463.1991.tb05156.x.
31. Fischetti VA. 2005. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 13:491-496. http://dx.doi.org/10.1016/j.tim.2005.08.007.
32. Nelson D, Schuch R, Chahales P, Zhu S, Fischetti VA. 2006. PlyC: a multimeric bacteriophage lysin. Proc Natl Acad Sci U S A 103:10765-10770. http://dx.doi.org/10.1073/pnas.0604521103.
33. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603-1612. http://dx.doi.org/10.1128/AAC.01625-09.
34. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. 2013. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57:2743-2750. http://dx.doi.org/10.1128/AAC.02526-12.
35. Schuch R, Pelzek AJ, Raz A, Euler CW, Ryan PA, Winer BY, Farnsworth A, Bhaskaran SS, Stebbins CE, Xu Y, Clifford A, Bearss DJ, Vankayalapati H, Goldberg AR, Fischetti VA. 2013. Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One 8:e60754. http://dx.doi.org/10.1371/journal.pone.0060754.
36. Fenton M, Ross RP, McAuliffe O, O'Mahony J, Coffey A. 2011. Characterization of the staphylococcal bacteriophage lysin CHAP(K). J Appl Microbiol 111:1025-1035. http://dx.doi.org/10.1111/j.1365-2672.2011.05119.x.
37. Resch G, Moreillon P, Fischetti VA. 2011. A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int J Antimicrob Agents 38:516-521. http://dx.doi.org/10.1016/j.ijantimicag.2011.08.009.
38. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. 2011. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 55:738-744. http://dx.doi.org/10.1128/AAC.00890-10.
39. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889. http://dx.doi.org/10.1038/nature01026.
40. Loessner MJ. 2005. Bacteriophage endolysins-current state of research and applications. Curr Opin Microbiol 8:480-487. http://dx.doi.org/10.1016/j.mib.2005.06.002.
41. Sun X, Wang H, Zhang Y, Chen K, Davis B, Feng H. 2011. Mouse relapse model of Clostridium difficile infection. Infect Immun 79:2856-2864. http://dx.doi.org/10.1128/IAI.01336-10.
42. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. 2008. A mouse model of Clostridium difficileassociated disease. Gastroenterology 135:1984-1992. http://dx.doi.org/10.1053/j.gastro.2008.09.002.
43. Raz A, Fischetti VA. 2008. Sortase A localizes to distinct foci on the Streptococcus pyogenes membrane. Proc Natl Acad Sci U S A 105:18549-18554. http://dx.doi.org/10.1073/pnas.0808301105.
44. Yoong P, Schuch R, Nelson D, Fischetti VA. 2004. Identification of a broadly active phage lytic enzyme with lethal activity against antibioticresistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 186: 4808-4812. http://dx.doi.org/10.1128/JB.186.14.4808-4812.2004.
45. Fischetti VA. 2008. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 11:393-400. http://dx.doi.org/10.1016/j.mib.2008.09.012.
46. Root RK. 1999. Clinical infectious diseases: a practical approach. Oxford University Press, Inc., Oxford, United Kingdom.
47. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A 98:4107-4112. http://dx.doi.org/10.1073/pnas.061038398.
48. Lood R, Raz A, Molina H, Euler CW, Fischetti VA. 2014. A highly active and negatively charged Streptococcus pyogenes lysin with a rare D-alanyl-L-alanine endopeptidase activity protects mice against streptococcal bacteremia. Antimicrob Agents Chemother 58:3073-3084. http://dx.doi.org/10.1128/AAC.00115-14.
49. Porter CJ, Schuch R, Pelzek AJ, Buckle AM, McGowan S, Wilce MC, Rossjohn J, Russell R, Nelson D, Fischetti VA, Whisstock JC. 2007. The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J Mol Biol 366:540-550. http://dx.doi.org/10.1016/j.jmb.2006.11.056.
50. Low LY, Yang C, Perego M, Osterman A, Liddington RC. 2005. Structure and lytic activity of a Bacillus anthracis prophage endolysin. J Biol Chem 280:35433-35439. http://dx.doi.org/10.1074/jbc.M502723200.
51. Meroueh SO, Bencze KZ, Hesek D, Lee M, Fisher JF, Stemmler TL, Mobashery S. 2006. Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc Natl Acad Sci U S A 103:4404-4409. http://dx.doi.org/10.1073/pnas.0510182103.
52. Low LY, Yang C, Perego M, Osterman A, Liddington R. 2011. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins. J Biol Chem 286:34391-34403. http://dx.doi.org/10.1074/jbc.M111.244160.
53. Kim JS, Ward KK, Shah NR, Saenz CC, McHale MT, Plaxe SC. 2013. Excess risk of Clostridium difficile infection in ovarian cancer is related to exposure to broad-spectrum antibiotics. Support Care Cancer 21:3103-3107. http://dx.doi.org/10.1007/s00520-013-1888-2.
54. Mayer MJ, Garefalaki V, Spoerl R, Narbad A, Meijers R. 2011. Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol 193:5477-5486. http://dx.doi.org/10.1128/JB.00439-11.
55. Schmelcher M, Powell AM, Camp MJ, Pohl CS, Donovan DM. 2015. Synergistic streptococcal phage lambdaSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl Microbiol Biotechnol 99:8475-8486. http://dx.doi.org/10.1007/s00253-015-6579-0.
56. Pawlowski SW, Calabrese G, Kolling GL, Platts-Mills J, Freire R, Alcantara Warren C, Liu B, Sartor RB, Guerrant RL. 2010. Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J Infect Dis 202:1708-1712. http://dx.doi.org/10.1086/657086.
57. Theriot CM, Koumpouras CC, Carlson PE, Bergin II, Aronoff DM, Young VB. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. Gut Microbes 2:326-334. http://dx.doi.org/10.4161/gmic.19142.
58. Burke KE, Lamont JT. 2013. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatrics Soc 61: 1394-1398. http://dx.doi.org/10.1111/jgs.12378.
59. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407-415. http://dx.doi.org/10.1056/NEJMoa1205037.